Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCL8 | P10145 | 2/20 | 0.64 |
| ▸ | GLS | O94925 | 4/20 | 0.44 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.43 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.43 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | PNMT | P11086 | 1/20 | 0.42 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | FLT4 | P35916 | 2/20 | 0.41 |
| ▸ | ACP3 | P15309 | 1/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9321170 | 0.85 | CXCL8 (0.54) | CXCL8CYP1A2CYP3A4CYP2D6LMNA | |
| SCHEMBL17513421 | 0.85 | CXCL8 (0.60) | CXCL8CYP1A2CYP3A4CYP2D6NFKB1 | |
| SCHEMBL27603271 | 0.83 | CXCL8 (0.47) | CXCL8GLSAOC3ADRB2ADRB1 | |
| SCHEMBL4659044 | 0.82 | CXCL8 (0.63) | CXCL8GLSADRB2ADRB1ALDH1A1 | |
| SCHEMBL29718684 | 0.82 | CXCL8 (0.63) | CXCL8GLSADRB2ADRB1ALDH1A1 | |
| SCHEMBL663906 | 0.82 | CXCL8 (0.63) | CXCL8GLSADRB2ADRB1ALDH1A1 | |
| SCHEMBL29107358 | 0.82 | CXCL8 (0.46) | CXCL8GLSAOC3ADRB2ADRB1 | |
| SCHEMBL15695552 | 0.82 | CXCL8 (0.50) | CXCL8GLSAOC3ADRB2ADRB1 | |
| SCHEMBL5672222 | 0.82 | CXCL8 (0.63) | CXCL8GLSADRB2ADRB1ALDH1A1 | |
| SCHEMBL16798960 | 0.82 | CXCL8 (0.50) | CXCL8GLSAOC3ADRB2ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018039442-A1 | TREATMENT OF CANCER WITH INHIBITORS OF GLUTAMINASE | CALITHERA BIOSCIENCES, INC. (US) | 2018-03-01 | — | — | WO | disclosed |
| WO-2016160980-A1 | METHODS OF ADMINISTERING GLUTAMINASE INHIBITORS | CALITHERA BIOSCIENCES, INC. (US) | 2016-10-06 | — | — | WO | disclosed |
| US-8921380-B2 | Pyrazolo[1,5-a] pyrimidine compounds as CB1 receptor antagonist | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2014-12-30 | — | — | US | disclosed |
| US-8921380-B2 | Pyrazolo[1,5-a] pyrimidine compounds as CB1 receptor antagonist | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2014-12-30 | — | — | US | disclosed |
| US-8816119-B2 | Arylamide derivatives having antiandrogenic properties | MEDEIA THERAPEUTICS LTD (FI) | 2014-08-26 | — | — | US | disclosed |
| US-20130109750-A1 | NOVEL ARYLAMIDE DERIVATIVES HAVING ANTIANDROGENIC PROPERTIES | MEDEIA THERAPEUTICS LTD (FI) | 2013-05-02 | — | — | US | disclosed |
| US-20120202992-A1 | PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AS CB1 RECEPTOR ANTAGONIST | TANIMOTO KOICHI (JP) | 2012-08-09 | — | — | US | disclosed |
| US-20120202992-A1 | PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AS CB1 RECEPTOR ANTAGONIST | TANIMOTO KOICHI (JP) | 2012-08-09 | — | — | US | disclosed |
| US-8163759-B2 | Pyrazolo[1,5-A] pyrimidine compounds as CB1 receptor antagonist | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-04-24 | — | — | US | disclosed |
| US-8163759-B2 | Pyrazolo[1,5-A] pyrimidine compounds as CB1 receptor antagonist | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-04-24 | — | — | US | disclosed |
| US-7947712-B2 | Antiarthritic agents; asthma; chronic obstructive pulminary diosrders; atherosclerosis; vision defects; hepatitis; central nervous system disorders; cardiovascular disorders; wound healing agents; restenosis; cirrhosis; multiple sclerosis; glomerulonephritis; graft versus host disease; antidiabetic agent | WYETH LLC (US) | 2011-05-24 | — | — | US | disclosed |
| US-20090258867-A1 | PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AS CB1 RECEPTOR ANTAGONIST | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-10-15 | — | — | US | disclosed |
| US-20090258867-A1 | PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AS CB1 RECEPTOR ANTAGONIST | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-10-15 | — | — | US | disclosed |
| US-20080269213-A1 | 8-Hydroxyquinoline compounds and methods thereof | WYETH (US) | 2008-10-30 | — | — | US | disclosed |
| WO-2008016676-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | CYTOKINETICS, INCORPORATED (US) | 2008-02-07 | — | — | WO | disclosed |
| WO-2008004698-A2 | PYRAZOLO [1, 5-A] PYRIMIDINE COMPOUNDS AS CB1 RECEPTOR ANTAGONIST | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-01-10 | — | — | WO | disclosed |
| EP-1268484-A1 | CONDENSED IMIDAZOLES AS HISTAMINE H3 RECEPTOR LIGANDS | NOVO NORDISK A/S (DK) | 2003-01-02 | — | — | EP | disclosed |
| WO-2001068652-A1 | CONDENSED IMIDAZOLES AS HISTAMINE H3 RECEPTOR LIGANDS | NOVO NORDISK A/S (DK) | 2001-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202992-A1 | PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AS CB1 RECEPTOR ANTAGONIST | CNR1, CNR2, CCKAR | CXCL8 650/4885GLS 4076/4885AOC3 1178/4885 |
| US-20090258867-A1 | PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AS CB1 RECEPTOR ANTAGONIST | CNR1, CNR2, CCKAR | CXCL8 742/4885GLS 4069/4885AOC3 996/4885 |
| US-20080269213-A1 | 8-Hydroxyquinoline compounds and methods thereof | MMP8, MMP26, MMP9 | CXCL8 22/4885GLS 1136/4885AOC3 1539/4885 |
| US-20130109750-A1 | NOVEL ARYLAMIDE DERIVATIVES HAVING ANTIANDROGENIC PROPERTIES | AR, NR5A1, CYP19A1 | CXCL8 3403/4885GLS 191/4885AOC3 3648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.